(Q54347600)

28 May 2018

title

A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. (English)

1 reference

28 May 2018

0 references

1 reference

1 reference

1 reference

Kasia Owczarczyk

1

1 reference

28 May 2018

Preeti Lal

2

1 reference

28 May 2018

Alexander R Abbas

3

1 reference

28 May 2018

Kristen Wolslegel

4

1 reference

28 May 2018

Cecile T J Holweg

5

1 reference

28 May 2018

Wolfgang Dummer

6

1 reference

28 May 2018

Ariella Kelman

7

1 reference

28 May 2018

Paul Brunetta

8

1 reference

28 May 2018

Nicholas Lewin-Koh

9

1 reference

28 May 2018

Marco Sorani

10

1 reference

28 May 2018

Diane Leong

11

1 reference

28 May 2018

Paul Fielder

12

1 reference

28 May 2018

David Yocum

13

1 reference

28 May 2018

Carole Ho

14

1 reference

28 May 2018

Ward Ortmann

15

1 reference

28 May 2018

Michael J Townsend

16

1 reference

28 May 2018

Timothy W Behrens

17

1 reference

28 May 2018

language of work or name

English

0 references

publication date

1 September 2011

1 reference

28 May 2018

Science Translational Medicine

published in

1 reference

28 May 2018

volume

3

1 reference

28 May 2018

page(s)

101ra92

1 reference

28 May 2018

issue

101

1 reference

28 May 2018

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Maturation and trafficking markers on rotavirus-specific B cells during acute infection and convalescence in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

B cells in HIV infection and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Reliability and reproducibility of a RNA preamplification method for low-density array analysis from formalin-fixed paraffin-embedded breast cancer samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

TreeView: an application to display phylogenetic trees on personal computers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002432

10.1126/SCITRANSLMED.3002432

21 January 2018

Identifiers

DOI

1 reference

28 May 2018

PubMed ID

21937757

1 reference

28 May 2018